Adia Nutrition Inc. Secures IRB Approval for Autism Clinical Study

Reuters
2025/12/15
<a href="https://laohu8.com/S/ADIA">Adia Nutrition</a> Inc. Secures IRB Approval for Autism Clinical Study

Adia Nutrition Inc. has received approval from the independent Institutional Review Board (IRB) BeyondBound for its clinical study protocol focused on Autism Spectrum Disorder (ASD). The approved study, led by Adia Med of Winter Park LLC, will enroll 100 children ages 3-12 to investigate the therapeutic benefits of combining glutathione with umbilical cord blood-derived stem cells compared to glutathione alone. The study has been submitted to ClinicalTrials.gov and is in final review before becoming publicly visible. No grant or funding from multiple organizations is mentioned.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Adia Nutrition Inc. published the original content used to generate this news brief via Newsfile (Ref. ID: 278050) on December 15, 2025, and is solely responsible for the information contained therein.

免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。

熱議股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10